Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted drug shows promise for Hard-to-Treat cancers in early trial

NCT ID NCT06235983

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an experimental drug called LY3537982 in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goal was to measure how the drug moves through the body and to check its safety. Researchers also looked for signs that the drug might shrink tumors, but this is not a cure and ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Feb 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Native Chinese participants must be of an acceptable age to provide informed consent. * Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1). * Have disease with evidence of KRAS G12C mutation * Have a histologically or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and must be appropriate candidates for study treatment. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Have adequate laboratory parameters. * Must be able to swallow capsules or tablets. * Estimated life expectancy ≥12 weeks Exclusion Criteria: * Have disease suitable for local therapy administered with curative intent. * Have an active fungal, bacterial, and/or active untreated viral infection, * Have a serious pre-existing medical condition(s) that would preclude participation in this study. * Have a serious cardiac condition. * Have untreated active symptomatic central neural system (CNS) malignancy or metastasis and/or carcinomatous meningitis. * Have received prior treatment with any KRAS G12C small molecule inhibitor. * Females who are pregnant or lactating. * Have a known allergic reaction against any of the components of the study drug

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

Contacts and locations

Locations

  • Jilin Cancer Hospital

    Changchun, Jilin, 132000, China

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, Zhejiang, 310003, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.